WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011015380) METHOD FOR PROGNOSIS OF PULMONARY ARTERIAL HYPERTENSION BY DETECTING ANTI-PAR2-ANTIBODIES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/015380    International Application No.:    PCT/EP2010/004934
Publication Date: 10.02.2011 International Filing Date: 04.08.2010
IPC:
C07K 16/28 (2006.01), G01N 33/53 (2006.01), G01N 33/566 (2006.01)
Applicants: CELLTREND GMBH [DE/DE]; Im Biotechnologiepark 14943 Luckenwalde (DE) (For All Designated States Except US).
HEIDECKE, Harald [DE/DE]; (DE) (For US Only).
SCHULZE-FORSTER, Kai [DE/DE]; (DE) (For US Only)
Inventors: HEIDECKE, Harald; (DE).
SCHULZE-FORSTER, Kai; (DE)
Agent: VOSSIUS & PARTNER; Sieberstrasse 4 81675 Munich (DE)
Priority Data:
09167297.2 05.08.2009 EP
Title (EN) METHOD FOR PROGNOSIS OF PULMONARY ARTERIAL HYPERTENSION BY DETECTING ANTI-PAR2-ANTIBODIES
(FR) MÉTHODE DE PRONOSTIC DE L'HYPERTENSION ARTÉRIELLE PULMONAIRE PAR DÉTECTION DES ANTICORPS ANTI-PAR2
Abstract: front page image
(EN)The invention relates to a method for diagnosis of a disease, wherein presence or absence of an anti-PAR2 antibody is determined in a sample from a patient to be diagnosed. The disease according to the invention is in particular selected from the group of scleroderma, preeclampsia, systemic lupus erythematosus (SLE), graft rejection, fibrosis, cancer, cardiomyopathy, malignant hypertension, portal hypertension and sickle-cell disease. The invention further relates to the use of an inhibitor of an anti-PAR2 antibody or an inhibitor of a PAR2 for the production of a medicament as well as a method for removing PAR2 antibodies from isolated blood by means of plasmapheresis.
(FR)L'invention porte sur une méthode de diagnostic d'une maladie déterminant la présence ou l'absence, dans un prélèvement d'un patient, d'un anticorps anti-PAR2. La maladie est en particulier sélectionnée dans un groupe comprenant: la sclérodermie, la prééclampsie, le lupus érythémateux systémique (SLE), le rejet de greffes, la fibrose, le cancer, la cardiomyopathie, l'hypertension maligne, l'hypertension portale et la drépanocytose. L'invention porte également sur l'utilisation d'un inhibiteur d'un anticorps anti-PAR2 ou d'un anticorps du PAR2 pour la production d'un médicament, et sur une méthode d'extraction par plasmaphérèse d'anticorps du PAR2 de sang isolé.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)